TG Therapeutics, Inc. Announces Third Quarter 2012 Financial Results and ... Equities.com The following abstracts were accepted for presentation: Ublituximab (TG-1101), an Optimized Anti-CD20 Monoclonal Antibody, Demonstrates Greater NK-Mediated ADCC Than Rituximab in Waldenstrom's Macroglobulinemia Patients Supporting a ... |
